广东电价突然飙升

Medipost Reports Positive Phase 3 Results for CARTISTEM in Japan’s Knee Osteoarthritis Trial_蜘蛛资讯网

Seung-jin, Head of Medipost’s Global Business Division and CEO of its Japanese subsidiary, is speaking at a press conference to announce the results of the Phase 3 clinical trial for Cartistem in Jap

demonstrated statistically highly significant superior efficacy compared to the active control group in the WOMAC (p-value Lee emphasized that the Japanese Phase 3 trial's confirmation of CARTISTEM's

当前文章：http://2jgb.teqialen.cn/hat/rf3.html

发布时间：00:00:00